Santa J. Tumminia

Dr. Santa J. Tumminia


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2019 in Genes
Verified
Journal Article
Open access
PDF file
HGHarini Gudiseva
Harini Gudiseva
Jesse BerryJesse Berry
Jesse Berry
APAshley Polski
Ashley Polski
STSanta J. Tumminia
Santa J. Tumminia
JOJoan M. O'Brien
Joan M. O'Brien
Retinoblastoma (RB) is an inherited retinal disorder (IRD) caused by the mutation in the RB1 gene or, rarely, by alterations in the MYCN gene. In recent years, new treatment advances have increased ocular and visual preservation in the developed world. The management of RB has improved significantly in recent decades, from the use of external beam radiation to recently, more localized treatments. Determining the underlying genetic cause of RB is critical for timely management decisions. The advent of next-generation sequencing technologies have assisted in understanding the molecular pathology of RB. Liquid biopsy of the aqueous humor has also had significant potential implications for tumor management. Currently, patients’ genotypic information, along with RB phenotypic presentation, are considered carefully when making treatment decisions aimed at globe preservation. Advances in molecular testing that improve our understanding of the molecular pathology of RB, together with multiple directed treatment options, are critical for developing precision medicine strategies to treat this disease.

10 May 2013 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
DBDelphine Blain
Delphine Blain
KGK E Goetz
K E Goetz
RAR Ayyagari
R Ayyagari
STSanta J. Tumminia
Santa J. Tumminia

26 April 2017 in Cell & Bioscience
Verified
Journal Article
Open access
PDF file
JGJackson Gao
Jackson Gao
LDLeera D’sOuza
Leera D’sOuza
KWKeith Wetherby
Keith Wetherby
CAChristian Antolik
Christian Antolik
MRMelissa Reeves
Melissa Reeves
XWXinjing Wang
Xinjing Wang
Oculocutaneous albinism (OCA) is an autosomal recessive disorder. A significant portion of OCA patients has been found with a single pathogenic variant either in the TYR or the OCA2 gene. Diagnostic sequencing of the TYR and OCA2 genes is routinely used for molecular diagnosis of OCA subtypes. To study the possibility that genomic abnormalities with single or multiple exon involvement may account for a portion of the potential missing pathogenic variants (the second), we retrospectively analyzed the TYR gene by long range PCR and analyzed the target 2.7 kb deletion in the OCA2 gene spanning exon 7 in OCA patients with a single pathogenic variant in the target genes. In the 108 patients analyzed, we found that one patient was heterozygous for the 2.7 kb OCA2 gene deletion and this patient was positive with one pathogenic variant and one possibly pathogenic variant [c.1103C>T (p.Ala368Val) + c.913C>T (p.R305W)]. Further analysis of maternal DNA, and two additional OCA DNA homozygous for the 2.7 kb deletion, revealed that the phenotypically normal mother is heterozygous of the 2.7 kb deletion and homozygous of the p.R305W. The two previously reported patients with homozygous of the 2.7 kb deletion are also homozygous of p.R305W. Among the reported pathogenic variants, the pathogenicity of the p.R305W has been discussed intensively in literature. Our results indicate that p.R305W is unlikely a pathogenic variant. The possibility of linkage disequilibrium between p.R305W with the 2.7 kb deletion in OCA2 gene is also suggested.

1 April 2016 in Biopreservation and Biobanking
Verified
Journal Article
Closed access
RPRebecca S. Parrish
Rebecca S. Parrish
AGAlexandra V. Garafalo
Alexandra V. Garafalo
VNVida Ndifor
Vida Ndifor
KGKerry E. Goetz
Kerry E. Goetz
MRMelissa J. Reeves
Melissa J. Reeves
STSanta J. Tumminia
Santa J. Tumminia
Quality assurance and quality control (QA/QC) procedures are vital to good biorepository management. The National Eye Institute (NEI) core CLIA-certified laboratory of the eyeGENE® Network receives blood from individuals with inherited eye conditions and isolates DNA for clinical genetic diagnostic testing and research. Clinical genetic test results are returned to the affected individuals, making it imperative that sample integrity is preserved throughout laboratory processing. A clinically validated, short tandem repeat (STR)-based approach, termed Sample Confirmation Testing (SCT), was developed to ensure that no significant laboratory errors occurred during processing. SCT uses modified protocols from commercial kits to create and compare STR profiles for each participant's original blood and derived DNA. This QA/QC procedure has been performed on 47% of the more than 6000 participants in the eyeGENE Biorepository and has identified significant laboratory errors in 0.4% of samples tested. SCT improves the quality of the data returned to affected individuals and the data distributed to researchers using eyeGENE samples by ensuring the integrity of the samples and aiding in curation of the biorepository. This approach serves as a model for other repositories to improve sample quality and management procedures.

12 April 2022 in Genes
Verified
Journal Article
Open access
PDF file
CBChelsea Bender
Chelsea Bender
EWElizabeth Woo
Elizabeth Woo
BGBin Guan
Bin Guan
EUEhsan Ullah
Ehsan Ullah
EFEric Feng
Eric Feng
RHRobert B Hufnagel
Robert B Hufnagel
For disorders with X-linked inheritance, variants may be transmitted through multiple generations of carrier females before an affected male is ascertained. Pathogenic RS1 variants exclusively cause X-linked retinoschisis (XLRS). While RS1 is constrained to variation, recurrent variants are frequently observed in unrelated probands. Here, we investigate recurrent pathogenic variants to determine the relative burden of mutational hotspot and founder allele events to this phenomenon. A cohort RS1 variant analysis and standardized classification, including variant enrichment in the XLRS cohort and in RS1 functional domains, were performed on 332 unrelated XLRS probands. A total of 108 unique RS1 variants were identified. A subset of 19 recurrently observed RS1 variants were evaluated in 190 probands by a haplotype analysis, using microsatellite and single nucleotide polymorphisms. Fourteen variants had at least two probands with common variant-specific haplotypes over ~1.95 centimorgans (cM) flanking RS1. Overall, 99/190 of reportedly unrelated probands had 25 distinct shared haplotypes. Examination of this XLRS cohort for common RS1 haplotypes indicates that the founder effect plays a significant role in this disorder, including variants in mutational hotspots. This improves the accuracy of clinical variant classification and may be generalizable to other X-linked disorders.

1 May 2012 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
STSanta J. Tumminia
Santa J. Tumminia